Barbara Gayle Duncan

Insider Reports History

Location
C/O Intercept Pharmaceuticals, Inc., 18 Desbrosses Street, New York, NY
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Barbara Gayle Duncan
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Barbara Gayle Duncan:

Stock Role Class Num Shares Value Price $ Report Date Ownership
HALOZYME THERAPEUTICS, INC. Director Common Stock 19.9K $1.2M $60.22 May 1, 2025 Direct
Atea Pharmaceuticals, Inc. Director Common Stock 62.8K $185K $2.95 Jun 20, 2025 Direct
Atea Pharmaceuticals, Inc. Director Restricted Stock Units 0 $103K $3.49 Jun 20, 2025 Direct
Adaptimmune Therapeutics PLC Director Option to purchase Ordinary Shares 500K Jul 1, 2022 Direct
Ovid Therapeutics Inc. Director Stock Option (right to buy) 45K Feb 20, 2025 Direct
Atea Pharmaceuticals, Inc. Director Stock Option (Right to Buy) 41.2K Jun 20, 2025 Direct
Fusion Pharmaceuticals Inc. Director Stock Opion (Right to Buy) 17K Jun 14, 2023 Direct
HALOZYME THERAPEUTICS, INC. Director Option to Purchase Common Stock 5.75K May 1, 2025 Direct
Fusion Pharmaceuticals Inc. Director Stock Option (Right to Buy) 0 Jun 4, 2024 Direct
Jounce Therapeutics, Inc. Director Stock Option (Right to Buy) 0 May 3, 2023 Direct

Insider Reports Filed by Barbara Gayle Duncan

Symbol Company Period Transactions Value $ Form Type Date Filed Role
AVIR Atea Pharmaceuticals, Inc. Jun 20, 2025 4 $0 4 Jun 24, 2025 Director
HALO HALOZYME THERAPEUTICS, INC. May 1, 2025 2 $0 4 May 2, 2025 Director
OVID Ovid Therapeutics Inc. Feb 20, 2025 1 $0 4 Jun 18, 2025 Director
OVID Ovid Therapeutics Inc. Dec 12, 2024 1 $0 4 Dec 16, 2024 Director
AVIR Atea Pharmaceuticals, Inc. Jun 21, 2024 2 $0 4 Jun 21, 2024 Director
AVIR Atea Pharmaceuticals, Inc. Jun 16, 2024 2 $0 4 Jun 18, 2024 Director
FUSN Fusion Pharmaceuticals Inc. Jun 4, 2024 4 $0 4 Jun 4, 2024 Director
HALO HALOZYME THERAPEUTICS, INC. Apr 25, 2024 2 $0 4 Apr 29, 2024 Director
OVID Ovid Therapeutics Inc. Feb 22, 2024 1 $0 4 Feb 26, 2024 Director
AVIR Atea Pharmaceuticals, Inc. Jun 16, 2023 2 $0 4 Jun 21, 2023 Director
FUSN Fusion Pharmaceuticals Inc. Jun 14, 2023 1 $0 4 Jun 14, 2023 Director
HALO HALOZYME THERAPEUTICS, INC. May 5, 2023 2 $0 4 May 9, 2023 Director
JNCE Jounce Therapeutics, Inc. May 3, 2023 7 $0 4 May 4, 2023 Director
OVID Ovid Therapeutics Inc. Feb 23, 2023 1 $0 4 Feb 27, 2023 Director
HALO HALOZYME THERAPEUTICS, INC. Feb 3, 2023 1 $0 4 Feb 7, 2023 Director
HALO HALOZYME THERAPEUTICS, INC. Feb 3, 2023 0 $0 3 Feb 6, 2023 Director
ADAP Adaptimmune Therapeutics PLC Jul 1, 2022 1 $0 4 Jul 1, 2022 Director
JNCE Jounce Therapeutics, Inc. Jun 24, 2022 1 $0 4 Jun 28, 2022 Director
AVIR Atea Pharmaceuticals, Inc. Jun 17, 2022 1 $0 4 Jun 21, 2022 Director
FUSN Fusion Pharmaceuticals Inc. Jun 14, 2022 1 $0 4 Jun 22, 2022 Director
OVID Ovid Therapeutics Inc. Apr 8, 2022 1 $0 4 Apr 12, 2022 Director
OVID Ovid Therapeutics Inc. Feb 3, 2022 1 $0 4 Feb 4, 2022 Director
ADAP Adaptimmune Therapeutics PLC Jul 1, 2021 1 $0 4 Jul 2, 2021 Director
JNCE Jounce Therapeutics, Inc. Jun 18, 2021 1 $0 4 Jun 22, 2021 Director
AVIR Atea Pharmaceuticals, Inc. Jun 18, 2021 1 $0 4 Jun 21, 2021 Director
OVID Ovid Therapeutics Inc. Jun 11, 2021 1 $0 4 Jun 11, 2021 Director
FUSN Fusion Pharmaceuticals Inc. Jun 4, 2021 1 $0 4 Jun 7, 2021 Director
OVID Ovid Therapeutics Inc. May 17, 2021 1 $0 4 May 18, 2021 Director